P86. Impact of reoperations on cost of care in adult spinal deformity surgery

Abstract

<h3>BACKGROUND CONTEXT</h3> Reoperations following adult spinal deformity (ASD) surgery place a significant burden on patient quality of life and overall health care costs. Despite the common knowledge of frequently occurring complications following ASD surgery that require reoperation, little is known on the cost and timing of these complications. Attempts to optimize the cost effectiveness of ASD surgery requires careful examination of the overall impact, frequency and timing of complications requiring reoperation on total cost of care. <h3>PURPOSE</h3> The primary aim of our study was to ascertain the percentage of total cost of care attributed to reoperations, identify the costliest complications requiring reoperation following index surgery and to determine the timing of these complications. <h3>STUDY DESIGN/SETTING</h3> Retrospective analysis of a prospective, multicenter study. <h3>PATIENT SAMPLE</h3> ASD patients with >4 level fusion and eligible for minimum 2-year follow-up were included. <h3>OUTCOME MEASURES</h3> Reoperation rates, Total cost of care. <h3>METHODS</h3> ASD patients with >4 level fusion with 2-year follow-up were included. Index and total episode of care (EOC) costs were calculated using Medicare's inpatient prospective payment system (IPPS) for MS-DRGs 453-460 and adjusted for inflation to 2020 real dollars. QALYs gained were calculated using baseline, 1-year, and 2-year SF-6D scores. Complication categories included: PJK (proximal junctional kyphosis), adjacent segment disease, pseudarthrosis, neurologic complications, malignment, implant malposition, and infections. <h3>RESULTS</h3> DRG data for index and revision surgery was available for 505/889 patients. Mean age was 62.5+12.4 years, 76% women. Eighty-nine patients (18%) required a total of 114 reoperations (range 1-5 per patient). The mean index EOC for the whole cohort was $72,718, compared to a mean cost of $59,130 for each reoperation. Accounting for all reoperations, the tEOC in the revision group was 2.1-times higher than the non-revision group ($151,913 vs $71,978, p<0.0001). The 2-year QALY gain in the revision group was significantly higher than the non-revision group (0.08 vs 0.03, p<0.01). The two most common complications requiring reoperations were PJK (41.2%) and pseudarthrosis (36.8%). Reoperations for PJK and pseudoarthrosis collectively accounted for 77% of reoperation costs, but the majority (53%) occurred after 2 years of index surgery. Infections, implant malposition, or neurologic complications (33% each) were most common requiring reoperations within 30 days of index surgery. <h3>CONCLUSIONS</h3> PJK and pseudarthrosis were the two most common complications requiring reoperation and most occurred most frequently over 2 years after index surgery. Collectively, they contributed to 77% of the total reoperation costs. Efforts to optimize the cost effectiveness of ASD surgery should focus on effective methods to mitigate risk of PJK and pseudarthrosis. <h3>FDA DEVICE/DRUG STATUS</h3> This abstract does not discuss or include any applicable devices or drugs.